Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19941500 | 0.84 | CA12 (0.55) | RECQLTSHRTDP1ALDH1A1LOXL2 | |
| SCHEMBL19580461 | 0.83 | PSIP1 (0.54) | LOXL2CA1CA2CA9CA12 | |
| SCHEMBL1449580 | 0.82 | TSHR (0.50) | RECQLTSHRCYP3A4TDP1ALDH1A1 | |
| SCHEMBL3442462 | 0.81 | GAA (0.48) | RECQLTSHRCYP3A4TDP1ALDH1A1 | |
| SCHEMBL4503685 | 0.80 | CA2 (0.52) | ALDH1A1CA2KMT2ARCE1 | |
| SCHEMBL2984207 | 0.80 | CA1 (0.62) | RECQLTSHRCYP3A4TDP1ALDH1A1 | |
| SCHEMBL515055 | 0.80 | KMT2A (0.50) | RECQLCYP3A4TDP1ALDH1A1GAA | |
| SCHEMBL12089981 | 0.79 | IDO1 (0.45) | ALDH1A1GAALMNAMAPT | |
| SCHEMBL3950901 | 0.79 | CA2 (0.63) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL18517162 | 0.78 | ALDH1A1 (0.40) | TSHRTDP1ALDH1A1LMNACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0382570-B1 | Indole derivatives | GLAXO GROUP LTD (GB) | 1993-12-08 | — | — | EP | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5001135-A | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-03-19 | — | — | US | disclosed |
| EP-0382570-A1 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1990-08-16 | — | — | EP | disclosed |
| US-4431585-A | THIAZOLE AND THIOPHENE DYES; DIAZOTIZATION; COUPLING | CASSELLA AKTIENGESELLSCHAFT (DE) | 1984-02-14 | — | — | US | disclosed |
| US-4329283-A | DISPERSE DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-11 | — | — | US | disclosed |
| EP-0035671-A1 | Water-insoluble azo dyestuffs, methods for their preparation and their use in dyeing and printing synthetic hydrophobic fibre materials | CASSELLA Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | disclosed |
| US-4247456-A | Water-insoluble monoazo pyridone dye | CASSELLA AKTIENGESELLSCHAFT (DE) | 1981-01-27 | — | — | US | disclosed |
| US-3957749-A | WATER-INSOLUBLE MONOAZO PYRIDINE DYES | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | RECQL 2300/4885TSHR 562/4885CYP3A4 2794/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | RECQL 916/4885TSHR 3945/4885CYP3A4 2048/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | RECQL 162/4885TSHR 2219/4885CYP3A4 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.